Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC

Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC

Introduction: Durvalumab after concurrent chemoradiation (CCRT) for NSCLC improves survival, but only in a subset of patients. We investigated the effect of severe radiation-induced lymphopenia (sRIL) on survival in these patients. Methods: Outcomes after CCRT (2010–2019) or CCRT followed by durvalu...

Full description

Bibliographic Details
Main Authors: Wang Jing, MD, Ting Xu, PhD, Lirong Wu, MD, Pablo B. Lopez, MD, Clemens Grassberger, PhD, Susannah G. Ellsworth, MD, Radhe Mohan, PhD, Brian P. Hobbs, PhD, George R. Blumenschein, MD, Janet Tu, MD, Mehmet Altan, MD, Percy Lee, MD, Zhongxing Liao, MD, Steven H. Lin, MD, PhD
Format: Article
Language:English
Published: Elsevier 2022-09-01
Series:JTO Clinical and Research Reports
Subjects:
NSCLC
Lymphopenia
Radiation
Immunotherapy
Durvalumab
Consolidative therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364322001151

Internet

http://www.sciencedirect.com/science/article/pii/S2666364322001151

Similar Items